ArticleThe Lancet. Microbe2021
Globally diverse
Article in The Lancet. Microbe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 60 citations in OpenAlex.
- Algorithmic Determinants of Performance Heterogeneity in Whole-Genome Sequencing-Based Prediction of Drug Resistance inMicroorganisms · 2026Review
- Long-term spatiotemporal evolution of drug-resistant Mycobacterium tuberculosis in China.Nature communications · 2026Article
- Profile of Priority Antimicrobial-Resistant Pathogens and the Behavior of Multidrug-Resistant Tuberculosis in the Santiago de Cali District, Colombia.Pathogens (Basel, Switzerland) · 2026Article
- Reviving Old Antibiotics: New Indications and Therapeutic Perspectives-A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Drug Exposure Dictates Evolutionary Dynamics of Drug-Resistant Tuberculosis: A Longitudinal Cohort Study in Beijing, China.Infection and drug resistance · 2026Article
- Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and DisputedPathogens (Basel, Switzerland) · 2025Review
- Ecology, global diversity and evolutionary mechanisms in the Mycobacterium tuberculosis complex.Nature reviews. Microbiology · 2025Review
- Longitudinal phenotypic and genomic evidence revealing increased risk of drug resistance accumulation in tuberculosis patients in the counties of central China.Microbiology spectrum · 2025Article
- RpoB mutation patterns in Rifampicin-resistant tuberculosis: a Jiangxi Province study, 2021-2023.Scientific reports · 2025Article
- Global epidemiology of Mycobacterium tuberculosis lineage 4 insights from Ecuadorian genomic data.Scientific reports · 2025Article
- Epidemiological changes in tuberculosis and genotyping characteristics ofFrontiers in microbiology · 2025Review
- Molecular epidemiology ofJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Drug-resistant tuberculosis: a persistent global health concern.Nature reviews. Microbiology · 2024Review
- The Impact of the Mycobacterium tuberculosis RDRio Subfamily on Multidrug-Resistant Tuberculosis in Latin America: A Comprehensive Review.The American journal of tropical medicine and hygiene · 2024Review
- Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.BMJ global health · 2024Article
- Article
- ChatGPT, GPT-4, and Other Large Language Models: The Next Revolution for Clinical Microbiology?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Phase variation as a major mechanism of adaptation inProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Analysis of Genome-Wide Mutational Dependence in Naturally Evolving Mycobacterium tuberculosis Populations.Molecular biology and evolution · 2023Article
- Evolution and epidemic success of Mycobacterium tuberculosis in eastern China: evidence from a prospective study.BMC genomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
background
methodsWe did a retrospective analysis of WGS data. We curated a set of clinical
findingsBetween Jan 1, 1987, and Sept 12, 2014, of 10 299
interpretationOur results highlight that both resistance transmission and amplification are contributing to disease burden globally but vary by country. The observation that wealthier nations are more likely to have old resistance (most recent common susceptible ancestor >20 years before isolation) suggests that programmatic improvements can reduce resistance amplification, but that fit resistant strains can circulate for decades subsequently implies the need for continued surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.